Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI
Status:
Withdrawn
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Participants will be persons with type 2 diabetes who are likely to have fatty liver disease.
The investigators think that this medication will reduce fatty liver.
The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat
before and after subjects take a diabetes medication. The investigators will also collect a
small amount of blood to measure liver, kidney and hormone functions. This will be done 4
times. Also, at the time of the subject gets their first dose of medication they will have a
DEXA (low exposure x-ray often used in clinical practice to measure bone density and body
composition).
The goal of all of these studies is to determine whether the study drug lowers liver fat.
Phase:
Phase 4
Details
Lead Sponsor:
University of Missouri-Columbia
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Sitagliptin Phosphate